Wide Ranks

ILMN

Illumina, Inc.

144.36

Top Statistics
Market Cap 22 B Forward PE 32.45 Revenue Growth -3.50 %
Current Ratio 2.43 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -36.10 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 33.74 Enterprise / Revenue 5.61 Price To Sales Trailing12 Months 5.22
Profitability
Profit Margins -36.10 % Operating Margins 23.98 %
Balance Sheet
Total Cash 939 M Total Cash Per Share 5.92 Total Debt 2 B
Total Debt To Equity 125.83 Current Ratio 2.43 Book Value Per Share 13.45
All Measures
Short Ratio 340.00 % Message Board Id finmb_29753 Fax 858 202 4545
Shares Short Prior Month 6 M Return On Equity -0.3951 City San Diego
Uuid c76f8ba3-209c-315d-a776-1d132bd357c6 Previous Close 142.95 First Trade Date Epoch Utc 964 M
Book Value 13.45 Beta 1.13 Total Debt 2 B
Volume 1 M Price To Book 10.73 Last Split Date 1 B
Fifty Two Week Low 96.53 Total Cash Per Share 5.92 Total Revenue 4 B
Shares Short Previous Month Date 1 B Target Median Price 164.00 Max Age 86400
Recommendation Mean 2.12 Sand P52 Week Change 0.3133 Operating Margins 23.98 %
Target Mean Price 164.60 Net Income To Common -1584999936 Short Percent Of Float 0.0467
Implied Shares Outstanding 158 M Trailing Peg Ratio 62.20 % Last Fiscal Year End 1 B
Average Daily Volume10 Day 2 M Average Volume10days 2 M Total Cash 939 M
Next Fiscal Year End 1 B Revenue Per Share 27.65 Held Percent Insiders 0.0027
Ebitda Margins 16.63 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 142.95 Target Low Price 120.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 141.42 Open 144.11
Free Cashflow 343 M State CA Dividend Yield 0.00 %
Return On Assets 0.0262 Time Zone Short Name EST Trailing Eps -9.98
Day Low 143.25 Address1 5200 Illumina Way Shares Outstanding 158 M
Price Hint 2 Target High Price 254.00 Website https://www.illumina.com
52 Week Change 0.4556 Average Volume 1 M Forward Eps 4.42
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 169.60 %
Last Split Factor 1028:1000 Regular Market Day High 146.30 Is_sp_500 False
Profit Margins -36.10 % Debt To Equity 125.83 Fifty Two Week High 156.66
Day High 146.30 Shares Short 6 M Regular Market Open 144.11
Industry Key diagnostics-research Earnings Growth 0.00 % Enterprise To Revenue 5.61
Revenue Growth -3.50 % Shares Percent Shares Out 0.0413 Operating Cashflow 697 M
Currency USD Time Zone Full Name America/New_York Market Cap 22 B
Is_nasdaq_100 True Zip 92122 Quote Type EQUITY
Industry Diagnostics & Research Long Name Illumina, Inc. Regular Market Day Low 143.25
Held Percent Institutions 0.9518 Current Price 144.36 Enterprise To Ebitda 33.74
Financial Currency USD Current Ratio 2.43 Gross Margins 67.61 %
Industry Disp Diagnostics & Research Number Of Analyst Opinions 25 Country United States
Float Shares 158 M Two Hundred Day Average 125.51 Ir Website http://investor.illumina.com/phoenix.zhtml?c=121127&p=IROL-irhome
Enterprise Value 24 B Price To Sales Trailing12 Months 5.22 Forward PE 32.45
Regular Market Volume 1 M Ebitda 730 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.

It operates through Core Illumina and GRAIL segments.

The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test.

In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications.

The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

It markets and distributes its products directly to customers, as well as through life-science distributors.

Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.